《艾滋病患者高活性抗逆转录病毒治疗相关的免疫重建炎性综合征的发病机制》

  • 来源专题:艾滋病防治
  • 编译者: 门佩璇
  • 发布时间:2014-09-26
  • 本研究探讨了艾滋病患者接受高活性抗逆转录病毒疗法 (HAART) 后免疫重建炎症反应综合征 (IRIS) 的免疫发病机制。该项前瞻性队列研究共纳入了238例接受了最初的HAART治疗的艾滋病患者。分别于研究基线时、接受HAART12周、24周后和出现IRIS时采集患者的血样。通过流式细胞仪或酶联免疫吸附法分别测定淋巴细胞亚群、Th1和Th2细胞因子、IL-7的水平。238例患者中,有47例发生了IRIS。在初始治疗后的24周后,出现IRIS和未出现IRIS患者的初始、记忆和活化CD4 + 和 CD8 + 细胞的比例没有显著差异。出现IRIS的患者组CD4 + CD25 + Foxp3 + 调节T细胞的比例在治疗前,治疗后12周、24周和出现IRIS时均明显低于未出现IRIS组的比例。此外,在治疗后4周和IRIS出现时,IRIS组的IL-2和IFN-γ水平均显著高于未出现IRIS组;IL-4和IL-10水平则明显低于未出现IRIS组。血浆IL-7水平随着HAART治疗的开展逐渐降低,且在所有的时间点上,IRIS组的IL-7水平均显著高于另一组。研究结果提示,Th1/Th2、持续降低的CD4 + CD25 + Fox3 + 比例和高IL-7水平可能是接受HAART治疗患者出现IRIS疾病进展的关键因素。

相关报告
  • 《PPARγ与RBP4基因变异体对艾滋病患者代谢综合征的逆转录病毒的影响》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2012-11-14
    • BACKGROUND: PPARγ and RBP4 are known to regulate lipid and glucose metabolism and insulin resistance. The influences of PPARγ (C1431T and Pro12Ala) and RBP4 (-803GA) polymorphisms on metabolic syndrome in HIV-infected patients receiving anti-retroviral therapy were examined in this study. MATERIALS AND METHODS: A cross-sectional study of HIV-1 infected adults with antiretroviral therapy for more than one year in the National Cheng Kung University Hospital was conducted. The gene polymorphisms were determined by quantitative PCR. RESULTS: Ninety-one patients were included in the study. Eighty-two (90.1%) patients were males with a mean age of 44.4 years. For the C1431T polymorphism in PPARγ, while patients with the T allele (48.4%) had trends toward lower rate of hypertriglyceridemia, the borderline significance together with insignificant power did not support the protective effect of the T allele against development of hypertriglyceridemia. For the Pro12Ala polymorphism in PPARγ, although patients with the Pro/Ala genotype (8.8%) had a higher level of serum LDL (138.0 vs. 111.5 mg/dl, P = 0.04) and trends toward higher rates of hypercholesterolemia and serum LDL>110 mg/dl, these variables were found to be independent of the Pro/Ala genotype in the multivariate analysis. For the -803GA polymorphism in RBP4, patients with the A allele (23.1%) more often had insulin resistance (HOMA>3.8; 33.3 vs. 8.7%, P = 0.01) and more often received anti-hypoglycemic drugs (14.3 vs. 1.4%, P = 0.04). The detrimental effect of the A allele in RBP4 -803GA polymorphism on development of insulin resistance was supported by the multivariate analysis adjusting for covariates. CONCLUSION: The impacts of PPARγ C1431T and Pro12Ala polymorphisms on metabolism in HIV-infected patients are not significant. RBP4 -803GA polymorphism has increased risk of insulin resistance in HIV-infected patients with anti-retroviral therapy.
  • 《英国艾滋病患者高活性抗逆转录病毒疗法的多中心群组研究》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-14
    • Objectives To investigate whether there is evidence that an increasing proportion of HIV infected patients is starting to experience increases in viral load and decreases in CD4 cell count that are consistent with exhaustion of available treatment options. Design Multicentre cohort study. Setting Six large HIV treatment centres in southeast England. Participants All individuals seen for care between 1 January 1996 and 31 December 2002. Main outcome measures Exposure to individual antiretroviral drugs and drug classes, CD4 count, plasma HIV RNA burden. Results Information is available on 16 593 individuals (13 378 (80.6%) male patients, 10 340 (62.3%) infected via homosexual or bisexual sex, 4426 (26.7%) infected via heterosexual sex, median age 34 years). Overall, 10 207 of the 16 593 patients (61.5%) have been exposed to any antiretroviral therapy. This proportion increased from 41.2% of patients under follow up at the end of 1996 to 71.3% of those under follow up in 2002. The median CD4 count and HIV RNA burden of patients under follow up in each year changed from 270 cells/mm3 and 4.34 log10 copies/ml in 1996 to 408 cells/mm3 and 1.89 log10 copies/ml, respectively, in 2002. By 2002, 3060 (38%) of patients who had ever been treated with antiretroviral therapy had experienced all three main classes. Of these, around one quarter had evidence of "viral load failure" with all these three classes. Patients with three class failure were more likely to have an HIV RNA burden > 2.7 log10 copies/ml and a CD4 count < 200 cells/mm3. Conclusions The proportion of individuals with HIV infection in the United Kingdom who have been treated has increased gradually over time. A substantial proportion of these patients seem to be in danger of exhausting their options for antiretroviral treatment. New drugs with low toxicity, which are not associated with cross resistance to existing drugs, are urgently needed for such patients.